We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel miRNA Assay Assesses Pancreatic Masses

By LabMedica International staff writers
Posted on 27 Feb 2012
A miRNA test aids physicians in the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive.

The test analyzes the expression levels of small, regulatory fine needle aspirate (FNA) molecules known as microRNA’s (miRNA). More...
An algorithm calculates a score between 0 and 1 by measuring the expression levels of seven miRNAs, and this determines whether or not PDAC has been identified.

The Asuragen, Inc. (Austin, TX, USA) miRNA assay, called the miRInform pancreas test, is immediately available in the company's College of American Pathologists (CAP)-accredited (Clinical Laboratory Improvement Amendments (CLIA) laboratory. miRInform pancreas is performed on FNA biopsies of solid lesions of PDAC patients.

“The development and commercialization of miRInform Pancreas for FNA specimens represents another breakthrough for Asuragen and capitalizes on our deep molecular expertise and unsurpassed foundation in using miRNAs for diagnostic and therapeutic applications,” commented Matt Winkler, PhD, CEO of Asuragen. “We believe miRNAs will prove to be highly relevant for many additional cancer diagnostic applications.

Related Links:

Asuragen, Inc.



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.